Quantify’s Alexander Rieem Dun and Jonas Banefelt are co-authors on a recent publication on the effects of intensity and adherence to lipid-lowering treatment on the risk of cardiovascular events in patients with […]
We are excited to introduce our new Director Dr. Béranger Lueza who joined our international Modelling, Access and Strategy unit this week. Béranger is based in Stockholm and has more […]
Earlier this week the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) based primarily on real-world evidence (RWE). The decision reflects the increasing importance of real-world data (RWD) […]
Today we are delighted to introduce Ethan O’Leary who joined our Stockholm team as a Research Analyst this Monday!
Ethan is currently finishing his Master’s in Economics from Stockholm School […]
Quantify’s Christoph Abé (PhD) publishes the largest-ever study associating bipolar disorder with abnormal brain changes over time in the renowned journal Biological Psychiatry, using neuroimaging data.
—
Our Lead Analyst, Christoph Abé (PhD) led an international […]
Check out this recent publication from Quantify, presenting a new conceptual framework in psoriasis that differentiates psoriasis severity from disease control (Link to article: https://onlinelibrary.wiley.com/doi/10.1111/bjd.21023https://lnkd.in/gJtZtENB). Authored by Quantify’s CEO Kirk Geale, […]
At Quantify, we work a lot with ICD codes. And we mean a lot! So much, in fact, that we have discovered some pretty obscure codes that you might not be aware […]
The 28th February is #rarediseaseday and we at Quantify want to help spread awareness of this important day as an estimated 300 million people of the world’s population are currently living with a rare disease.
At Quantify we are determined to […]